SI-BONE, Inc. (NASDAQ:SIBN) CEO Laura Francis Sells 12,385 Shares of Stock

SI-BONE, Inc. (NASDAQ:SIBN) CEO Laura Francis sold 12,385 shares of the firm’s stock in a transaction on Friday, May 16th. The shares were sold at an average price of $19.67, for a total transaction of $243,612.95. Following the completion of the transaction, the chief executive officer now owns 495,170 shares in the company, valued at $9,739,993.90. The trade was a 2.44% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Laura Francis also recently made the following trade(s):

• On Monday, May 19th, Laura Francis sold 5,412 shares of SI-BONE stock. The shares were sold at an average price of $19.49, for a total transaction of $105,479.88.
• On Wednesday, May 7th, Laura Francis sold 38,504 shares of SI-BONE stock. The shares were sold at an average price of $17.18, for a total value of $661,498.72.

SI-BONE Trading Up 1.3%

Shares of SIBN opened at $19.71 on Wednesday. The stock’s 50-day moving average price is $15.02 and its 200 day moving average price is $15.11. The company has a quick ratio of 7.22, a current ratio of 8.25 and a debt-to-equity ratio of 0.22. The firm has a market capitalization of $839.94 million, a price-to-earnings ratio of -21.42 and a beta of 0.82. SI-BONE, Inc. has a 12-month low of $11.70 and a 12-month high of $20.05.

SI-BONE (NASDAQ:SIBN) last issued its earnings results on Monday, May 5th. The company reported ($0.15) EPS for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.09. SI-BONE had a negative return on equity of 22.51% and a negative net margin of 23.82%. The business had revenue of $47.29 million during the quarter, compared to analyst estimates of $45.13 million. As a group, research analysts predict that SI-BONE, Inc. will post -0.78 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on SIBN shares. Needham & Company LLC restated a “buy” rating and set a $24.00 target price on shares of SI-BONE in a research note on Tuesday, May 6th. Truist Financial increased their price objective on SI-BONE from $20.00 to $22.00 and gave the company a “buy” rating in a research report on Tuesday, May 6th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $25.00 target price on shares of SI-BONE in a research report on Tuesday, May 6th.

Hedge Funds Weigh In On SI-BONE

Hedge funds and other institutional investors have recently made changes to their positions in the business. JPMorgan Chase & Co. increased its stake in SI-BONE by 14.7% in the third quarter. JPMorgan Chase & Co. now owns 177,793 shares of the company’s stock valued at $2,486,000 after acquiring an additional 22,732 shares during the period. Rhumbline Advisers boosted its holdings in SI-BONE by 3.0% during the fourth quarter. Rhumbline Advisers now owns 57,621 shares of the company’s stock valued at $808,000 after purchasing an additional 1,683 shares in the last quarter. MetLife Investment Management LLC grew its stake in shares of SI-BONE by 17.6% in the 4th quarter. MetLife Investment Management LLC now owns 27,421 shares of the company’s stock valued at $384,000 after purchasing an additional 4,104 shares during the period. Proficio Capital Partners LLC acquired a new position in shares of SI-BONE in the 4th quarter worth approximately $155,000. Finally, VELA Investment Management LLC lifted its position in shares of SI-BONE by 23.8% during the 4th quarter. VELA Investment Management LLC now owns 122,671 shares of the company’s stock worth $1,720,000 after buying an additional 23,592 shares during the period. 98.11% of the stock is owned by institutional investors.

About SI-BONE

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.